2012The Professional Medical JournalOpen access

POSTPARTUM HEMORRHAGE;

ROBINA ALI, FARZANA HINA

Open full text 4 citations

Abstract

Introduction: Worldwide PPH remains one of the most common cause of maternal mortality and is largely preventable maternaldeaths mainly in low income countries. 80% of it occurs due to uterine atony and uterotonics can decrease the risk of uterine atony. Misoprostolhas powerful uterotonic effect because it is well absorbed and has potential to be used more widely than would be possible with injectableuterotonics alone. Objective: The objective of this study is to compare efficacy of misoprostol with ergometrine in cesarean delivery formanagement of PPH. Study Design: Randomized controlled trial. Duration of study: The duration of study was six months from 1/1/2010 to30th/6/2010. Setting: Department of Gynae and obstetrics, DHQ hospital, Faisalabad. Subjects and methods: All patients fulfilling inclusioncriteria were included in study and before cesarean section Hb was carried out and Patients were divided into two groups, GP , and GP . GP 1 2 1was given 800 ug MP per rectal just before starting cesarean Section and GP was given intravenous ergometrine at delivery of head or anterior 2shoulder. Blood loss was measured objectively after delivery of the baby with help of standard size kidney tray of 500cc and post operative Hbwas Carried out on 3rd post operative day. Results: 187 Patients were randomly allocated in GP and GP each. In GP , misoprostol was given 1 2 1800 μg per rectal just before starting cesarean section and 13 patients (7%) out of 187 have blood loss more than 500ml measured by standardsize kidney tray while in GP intravenous ergometrine was given at delivery of the head and in this group 25 patients (13.5%) out of 187 had 2blood loss more than 500ml, so misoprostol was found to be a better uterotonic than ergometrine for prevention of PPH. On the third postoperative day Hb was carried out and in GP 13 patients (7%) out of 187 had their Hb less than 9 g/dl while in GP 25 patients (13.5%) had Hb less 1 2than 9 g/d1. Conclusions: Mp is stable, cost effective and easily administrable drug and was found to be comparatively more powerfuluterotonic than ergometrine for preventing uterine atony.

Open-access reader

About this research paper

What this paper is about

Introduction: Worldwide PPH remains one of the most common cause of maternal mortality and is largely preventable maternaldeaths mainly in low income countries. 80% of it occurs due to uterine atony and uterotonics can decrease the risk of uterine atony. Misoprostolhas powerful uterotonic effect because it is well absorbed and has potential to be used more widely than would be possible with injectableuterotonics alone. Objective: The objective of this study is to compare efficacy of misoprostol with ergometrine in cesarean delivery formanagement of PPH. Study Design: Randomized controlled trial. Duration of study: The duration of study was six months from 1/1/2010 to30th/6/2010. Setting: Department of Gynae and obstetrics, DHQ hospital, Faisalabad. Subjects and methods: All patients fulfilling inclusioncriteria were included in study and before cesarean section Hb was carried out and Patients were divided into two groups, GP , and GP . GP 1 2 1was given 800 ug MP per rectal just before starting cesarean Section and GP was given intravenous ergometrine at delivery of head or anterior 2shoulder. Blood loss was measured objectively after delivery of the baby with help of standard size kidney tray of 500cc and post operative Hbwas Carried out on 3rd post operative day. Results: 187 Patients were randomly allocated in GP and GP each. In GP , misoprostol was given 1 2 1800 μg per rectal just before starting cesarean section and 13 patients (7%) out of 187 have blood loss more than 500ml measured by standardsize kidney tray while in GP intravenous ergometrine was given at delivery of the head and in this group 25 patients (13.5%) out of 187 had 2blood loss more than 500ml, so misoprostol was found to be a better uterotonic than ergometrine for prevention of PPH. On the third postoperative day Hb was carried out and in GP 13 patients (7%) out of 187 had their Hb less than 9 g/dl while in GP 25 patients (13.5%) had Hb less 1 2than 9 g/d1. Conclusions: Mp is stable, cost effective and easily administrable drug and was found to be comparatively more powerfuluterotonic than ergometrine for preventing uterine atony.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction: Worldwide PPH remains one of the most common cause of maternal mortality and is largely preventable maternaldeaths mainly in low income countries. 80% of it occurs due to uterine atony and uterotonics can decrease the risk of uterine atony. Misoprostolhas powerful uterotonic effect because it is well absorbed and has potential to be used more widely than would be possible with injectableuterotonics alone. Objective: The objective of this study is to compare efficacy of misoprostol with ergometrine in cesarean delivery formanagement of PPH. Study Design: Randomized controlled trial. Duration of study: The duration of study was six months from 1/1/2010 to30th/6/2010. Setting: Department of Gynae and obstetrics, DHQ hospital, Faisalabad. Subjects and methods: All patients fulfilling inclusioncriteria were included in study and before cesarean section Hb was carried out and Patients were divided into two groups, GP , and GP . GP 1 2 1was given 800 ug MP per rectal just before starting cesarean Section and GP was given intravenous ergometrine at delivery of head or anterior 2shoulder. Blood loss was measured objectively after delivery of the baby with help of standard size kidney tray of 500cc and post operative Hbwas Carried out on 3rd post operative day. Results: 187 Patients were randomly allocated in GP and GP each. In GP , misoprostol was given 1 2 1800 μg per rectal just before starting cesarean section and 13 patients (7%) out of 187 have blood loss more than 500ml measured by standardsize kidney tray while in GP intravenous ergometrine was given at delivery of the head and in this group 25 patients (13.5%) out of 187 had 2blood loss more than 500ml, so misoprostol was found to be a better uterotonic than ergometrine for prevention of PPH. On the third postoperative day Hb was carried out and in GP 13 patients (7%) out of 187 had their Hb less than 9 g/dl while in GP 25 patients (13.5%) had Hb less 1 2than 9 g/d1. Conclusions: Mp is stable, cost effective and easily administrable drug and was found to be comparatively more powerfuluterotonic than ergometrine for preventing uterine atony.

Key concepts: Medicine, Ergometrine, Uterine atony, Uterotonic, Misoprostol, Obstetrics, Blood loss, Atony

Related papers

Back to paper searchBrowse research topicsOriginal source
POSTPARTUM HEMORRHAGE; — Research Paper | ScholarLens